Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients

• Published in: Journal of neurology Vol. 262; no. 6; pp. 1493 - 1503
• Main Authors: Ehinger, Johannes K., Morota, Saori, Hansson, Magnus J., Paul, Gesine, Elmér, Eskil
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2015; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - complications; Amyotrophic Lateral Sclerosis - pathology; Biomarkers; Blood; Blood Cells - pathology; Blood Cells - ultrastructure; Blood platelets; Case-Control Studies; Citrate (si)-Synthase - metabolism; Clinical Medicine; Cytochrome; Disease Progression; DNA, Mitochondrial - metabolism; Electron Transport Complex IV; Female; Humans; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Middle Aged; Mitochondria; Mitochondria - metabolism; Mitochondria - pathology; Mitochondria - ultrastructure; Mitochondrial Diseases - etiology; Mitochondrial DNA; Multienzyme Complexes - metabolism; Neurologi; Neurology; Neurons; Neuroradiology; Neurosciences; Original Communication; Otolaryngology; Patients; Prescription drugs; Respiration; Statistics, Nonparametric; Superoxide Dismutase; Sweden; Biomarkers; Motor neurons; Amyotrophic lateral sclerosis; Mitochondria; Mitochondrial complex IV deficiency
• ISSN: 0340-5354; 1432-1459; 1432-1459
• DOI: 10.1007/s00415-015-7737-0

Mitochondrial dysfunction is implicated in amyotrophic lateral sclerosis, where the progressive degeneration of motor neurons results in muscle atrophy, paralysis and death. Abnormalities in both central nervous system and muscle mitochondria have previously been demonstrated in patient samples, indicating systemic disease. In this case–control study, venous blood samples were acquired from 24 amyotrophic lateral sclerosis patients and 21 age-matched controls. Platelets and peripheral blood mononuclear cells were isolated and mitochondrial oxygen consumption measured in intact and permeabilized cells with additions of mitochondrial substrates, inhibitors and titration of an uncoupler. Respiratory values were normalized to cell count and for two markers of cellular mitochondrial content, citrate synthase activity and mitochondrial DNA, respectively. Mitochondrial function was correlated with clinical staging of disease severity. Complex IV (cytochrome c-oxidase)-activity normalized to mitochondrial content was decreased in platelets from amyotrophic lateral sclerosis patients both when normalized to citrate synthase activity and mitochondrial DNA copy number. In mononuclear cells, complex IV-activity was decreased when normalized to citrate synthase activity. Mitochondrial content was increased in amyotrophic lateral sclerosis patient platelets. In mononuclear cells, complex I activity declined and mitochondrial content increased progressively with advancing disease stage. The findings are, however, based on small subsets of patients and need to be confirmed. We conclude that when normalized to mitochondria-specific content, complex IV-activity is reduced in blood cells from amyotrophic lateral sclerosis patients and that there is an apparent compensatory increase in cellular mitochondrial content. This supports systemic involvement in amyotrophic lateral sclerosis and suggests further study of mitochondrial function in blood cells as a future biomarker for the disease.